CMCarole A. Marxer

Carole A. Marxer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Carole A. Marxer has a total of 50 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Risk of Adverse Kidney Outcomes in Families with MASLD: A Population-Based Multigenerational Cohort Study

    by Fahim Ebrahimi, Christian Eichhorn, Jiangwei Sun, David Bergman, Carole A. Marxer, Hannes Hagström, Juan J. Carrero, Jonas F. Ludvigsson

  • Open Access

    Histologic metabolic dysfunction–associated steatotic liver disease severity associated with a graded increase in peripheral artery disease risk

    by Shuai Yuan, Fahim Ebrahimi, Jiangwei Sun, Hannes Hagström, Carole A. Marxer, Michael G. Clark, Marijana Vujkovic, Scott M. Damrauer, Jonas F. Ludvigsson

  • Open Access

    Autoimmune disease in offspring of mothers with metabolic dysfunction-associated steatotic liver disease (MASLD): a nationwide cohort study

    by Carole A. Marxer, Fahim Ebrahimi, David Bergman, Jiangwei Sun, Hannes Hagström, Marcus Thuresson, Olof Stephansson, Jonas F. Ludvigsson

    Metabolic dysfunction-associated steatotic liver disease (MASLD) in pregnancy may disrupt physiological maternal immune adaptations, thereby altering fetal immune programming and increasing the long-term risk of autoimmune diseases (ADs) in offspring. This is a pressing public health concern, as both maternal MASLD and childhood-onset ADs are rising in prevalence worldwide. This nationwide cohort study included all singleton live-born offspring of mothers with biopsy-proven MASLD diagnosed in Sweden between 1992 and 2017. We matched the 239 identified MASLD offspring with up to 5 reference offspring ( n = 1,131) of mothers without known MASLD by maternal age at delivery, calendar year of delivery, and parity. We used multivariable Cox proportional hazard models to estimate adjusted hazard ratios (aHRs) for any AD up until 2023. We performed stratified analyses by histological stage of maternal MASLD (simple steatosis versus severe MASLD defined as either steatohepatitis, any stage of liver fibrosis, or cirrhosis). During a median of 18.4 years of follow-up (interquartile range [IQR] 13.2–23.8), 15 exposed offspring (incidence rate [IR] 3.4/1000 person-years) vs. 40 reference offspring (IR 1.9/1000 person-years) were diagnosed with AD. This corresponded to an aHR of 1.20 (95% CI 0.57–2.53). The risk of AD remained unchanged among 175 offspring born to mothers with simple steatosis (aHR 0.84, 95% CI 0.29–2.45), and was higher, but not significant, in 64 offspring of mothers with severe MASLD (aHR 1.98, 95% CI 0.67–5.84). We did not identify an association of maternal MASLD with AD in offspring. Larger studies with follow-up extending beyond early adulthood are, however, needed.


  • Open Access

    Higher Risk of Serious Infection in Offspring of Mothers With Biopsy‐Proven MASLD: A Nationwide Cohort Study

    by Carole A. Marxer, Fahim Ebrahimi, David Bergman, Jiangwei Sun, Hannes Hagström, Marcus Thuresson, Olof Stephansson, Jonas F. Ludvigsson

    Background: Metabolic dysfunction‐associated steatotic liver disease (MASLD) has been linked to an increased risk of serious infection, but the impact of in utero exposure to maternal MASLD on the risk of infection in offspring remains unknown. Methods: This nationwide cohort study included all singleton live born offspring exposed in utero to maternal biopsy‐proven MASLD (1992–2017) in Sweden. Offspring born to mothers with MASLD ( N = 239) were matched with up to five reference offspring ( N = 1131) of mothers without MASLD by maternal age at delivery, calendar year of delivery, and parity. We used multivariable Cox regression to estimate adjusted hazard ratios (aHRs) for incident serious infection up until 2023. Results were also stratified by maternal histological severity of MASLD (simple steatosis vs. severe MASLD including steatohepatitis, any stage of liver fibrosis or cirrhosis). Results: Over a median of 16.7 years of follow‐up, 56 incident serious infections occurred in MASLD offspring (incidence rate [IR] 15.8/1000 person‐years) and 140 incident serious infections occurred in reference offspring (IR 7.4/1000 person‐years), which corresponded to an aHR of 1.81 (95% CI 1.23–2.68). The aHRs for incident serious infection were similar to offspring of mothers with simple steatosis and severe MASLD (1.97 vs. 1.70). This association was primarily explained by early‐life infections (1‐year aHR 3.11, 95% CI 1.74–5.58), with severe MASLD potentially being a major factor in the observed association during the first year. Results remained consistent across subgroups. Discussion: Maternal MASLD, even simple steatosis, is associated with a higher hazard of serious offspring infection, highlighting the need for closer monitoring.


  • Open Access

    Mortality and Cancer in Offspring of Mothers With Biopsy‐Proven MASLD During Pregnancy: A Nationwide Cohort Study

    by Carole A. Marxer, Fahim Ebrahimi, David Bergman, Jiangwei Sun, Hannes Hagström, Marcus Thuresson, Olof Stephansson, Jonas F. Ludvigsson

    Background & Aims: Health‐related outcomes through early adulthood among offspring prenatally exposed to maternal metabolic dysfunction‐associated steatotic liver disease (MASLD) are insufficiently investigated. We aimed to study the risk of mortality and cancer in such offspring. Methods: This nationwide cohort study included all singleton live born offspring with prenatal exposure to maternal biopsy‐proven MASLD (1992–2017; N = 239) in Sweden. MASLD offspring were matched with up to five reference offspring ( N = 1131) of mothers without known MASLD by maternal age at delivery, calendar year of delivery, and parity. We used a multivariable Cox proportional hazard model to calculate adjusted hazard ratios (aHRs) with 95% confidence intervals (CIs) for mortality and cancer up until 31 December 2021. For mortality, we stratified by maternal MASLD severity (simple steatosis alone vs. severe MASLD comprising steatohepatitis, liver fibrosis or cirrhosis). Results: Over a median follow‐up of 16.9 years, two deaths occurred in offspring prenatally exposed to maternal MASLD (IR 0.5/1000 person‐years, 95% CI 0.1–1.8) and seven deaths in reference offspring (IR 0.4/1000 person‐years, 95% CI 0.1–0.8), which corresponded to an aHR of 1.78 (95% CI 0.27–11.97). Higher disease severity was not associated with an increased risk of death. We observed few cancer events with similar IR/1000 person‐years (0.2 [95% CI 0.0–1.4] vs. 0.3 [0.1–0.6] in reference offspring), which corresponded to an aHR of 0.64 (95% CI 0.07–5.95). Conclusions: We found no evidence that prenatal exposure to maternal MASLD affects the risk of death or cancer through early adulthood but larger studies are needed.


  • Open Access

    Comparative effectiveness and safety of dual antiplatelet therapy with ticagrelor vs. clopidogrel in older adults with acute coronary syndrome: a target trial emulation study

    by Carole A Marxer, Paul Hjemdahl, Juan J Carrero, Edouard L Fu

    Aims: There is conflicting trial evidence on the comparative effects of dual antiplatelet therapy (DAPT) with ticagrelor vs. clopidogrel in older patients with acute coronary syndromes (ACS). We aimed to assess the risk of major adverse cardiovascular events (MACE) and major bleeding in ACS patients ≥75 years initiating ticagrelor vs. clopidogrel treatment. Methods and results: We used healthcare data from the Stockholm region (2011–2021) to emulate a hypothetical target trial comparing ticagrelor vs. clopidogrel. MACE was defined as a composite of cardiovascular death, myocardial infarction, or stroke. Patients were followed for 12 months. Inverse probability of treatment weighting was used to adjust for 46 baseline confounders. We used weighted Cox proportional hazards regression to estimate hazard ratios (HRs) with 95% confidence intervals (CIs) and the weighted Aalen–Johansen estimator to estimate absolute risks (AR). Among 4637 older patients [median age, 81 years (IQR, 77–85)], 49% initiated DAPT with ticagrelor and 51% with clopidogrel. After weighting, all confounders were balanced. Ticagrelor was associated with a lower one-year MACE risk than clopidogrel (11.1% vs. 14.9%), corresponding to an AR difference of −3.8% (95%CI, −6.8, −0.8). The HR for ticagrelor vs. clopidogrel was 0.73 (95%CI, 0.56–0.95). There was no difference in the risk of major bleeding with one-year absolute risks of 4.3% with ticagrelor vs. 4.8% with clopidogrel, and a HR of 0.89 (95%CI, 0.63–1.27). Conclusion: In ACS patients aged ≥75 years, ticagrelor was associated with a lower risk of MACE than clopidogrel. There were no differences in major bleeding, although the confidence interval was wide.


  • Open Access

    Adverse pregnancy and birth outcomes in women with biopsy-proven MASLD: a nationwide cohort study

    by Carole A. Marxer, Fahim Ebrahimi, David Bergman, Jiangwei Sun, Hannes Hagström, Marcus Thuresson, Olof Stephansson, Jonas F. Ludvigsson


  • Open Access

    Changes in serum creatinine during and after pregnancy in female patients with or without chronic kidney disease: an observational study in UK primary care data

    by Carole A. Marxer, Julie M. Paik, Min Zhuo, Rishi J. Desai, Katrina Wilcox Hagberg, Susan S. Jick, Christoph R. Meier, Julia Spoendlin


  • Open Access

    Exposure to potentially teratogenic medications before and during the first trimester of pregnancy compared to women of childbearing age: A retrospective analysis of Swiss claims data (2015–2021)

    by Carole A. Marxer, Sereina M. Graber, Daniel Surbek, Alice Panchaud, Christoph R. Meier, Julia Spoendlin

    Introduction: Exposure to potentially teratogenic medications during pregnancy is underinvestigated in Switzerland. We aimed to assess exposure to potential teratogens preconceptionally, during the first trimester, and in women of childbearing age, and specifically explore the effectiveness of the valproate pregnancy prevention program (2018).Material and Methods: Retrospective study using the Swiss Helsana claims database. In a pregnancy cohort (2015–2021) and a cohort of women of childbearing age (2021 and 2018), we defined three 90‐day time periods: (1) first trimester, (2) preconceptional period (days 180–90 before pregnancy), and (3) January 01, 2021, and March 31, 2021 (women of childbearing age). During all periods, we quantified the exposure prevalence to at least one dispensed weak, proven, and unequivocally potent teratogen overall and by age strata. We quantified the exposure prevalence to each individual teratogen, and to valproate during pregnancy by calendar year to compare its use before and after the introduction of a pregnancy prevention program (2018). We investigated the use of systemic retinoids particularly isotretinoin in women of childbearing age.Results: Of 34 584 pregnant women, 1.4% were exposed to potential teratogens during the first trimester (weak: 1.3%, proven: 0.06%, unequivocally potent: 0.04%). During the preconceptional period, 2.9% were exposed to any teratogen compared to 4.7% of women of childbearing age (Ntotal = 95 059). Systemic glucocorticoids were the most prevalent weak teratogens during all time periods (75% of all claimed teratogens during the first trimester). In the first trimester, the antibiotic cotrimoxazole and the thyreostatic thiamazole (weak teratogens), ranked second and third, followed by the antiseizure medications carbamazepine and topiramate (proven teratogens). Among women of childbearing age, exposure to weak and proven teratogens increased with age, whereas exposure to unequivocally potent teratogens decreased with age. This was due to 2.3% of women <26 years who claimed systemic isotretinoin. Valproate use during pregnancy decreased after the introduction of a pregnancy prevention program (2.39/10 000 pregnancies [2015–2018] vs. 0.93/10 000 pregnancies [2019–2021]).Conclusions: Most medications with potential teratogenic effects dispensed to women of childbearing age and pregnant women were in the group of weak teratogenicity level, and many women discontinued treatment before pregnancy. Preliminary evidence suggests the valproate pregnancy prevention program in Switzerland may be beneficial.